Core Insights - SoundHound AI, Inc. reported a strong financial performance for Q3 2025, with revenue reaching $42.0 million, a 68% increase year-over-year [6][14] - The company is expanding its presence in key vertical markets and forming strategic partnerships to enhance its AI leadership through the Agentic+ framework [1][4] Financial Highlights - Revenue for Q3 2025 was $42.0 million, up from $25.1 million in Q3 2024, marking a 68% increase [6][14] - GAAP gross margin was 42.6%, while non-GAAP gross margin was 59.3% [6][14] - GAAP net loss was $109.3 million, compared to a loss of $21.8 million in the same quarter last year [6][14] - Adjusted EBITDA loss was $14.5 million, showing an improvement from a loss of $15.9 million in Q3 2024 [6][14] Business Developments - The company launched the Amelia 7.3 update, enhancing its voice AI capabilities with Speech-to-Meaning technology [7] - Significant contracts were secured across various sectors, including automotive, healthcare, and financial services, indicating a diverse customer base [12][19] - SoundHound is raising its full-year 2025 revenue outlook to a range of $165 - $180 million [18] Strategic Partnerships and Market Position - SoundHound is working with major brands in automotive and healthcare to deploy its AI solutions, including a custom assistant for a sports car brand and a pioneering AI solution for a precision medicine provider [12][19] - The company has established partnerships with leading technology distributors and service providers to enhance its market reach [12][19] Cash Flow and Liquidity - As of September 30, 2025, the company had total cash and cash equivalents of $269 million, with no debt [16]

New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growthMENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating ...

-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mut ...

Declares Quarterly Dividend of $0.68 per ShareLOUISVILLE, Ky., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 39 weeks ended September 30, 2025. Financial Results Financial results for the 13 and 39 weeks ended September 30, 2025 and September 24, 2024 were as follows: 13 Weeks Ended 39 Weeks Ended($000's, except per share amounts)September 30, 2025 September 24, 2024 % change September 30, 2025 September 24, 2024 % changeTotal rev ...

SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced the appointment of Craig Cornelius as a member of Sunrun’s board of directors (the “Board”). Mr. Cornelius brings two decades of industry experience across the renewable energy space. “I am excited to announce the appointment of Craig as our newest board member. Craig brings a wealth of experience and perspective, having led large, c ...

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter Vancouver, Canada, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announ ...

Revenue Growth, Operational Discipline, and Strategic Focus Position Blink for Solid Q4 Bowie, MD., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Blink Charging Co. (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator, and provider of electric vehicle (EV) charging equipment and services, today announced financial results for the third quarter ended September 30, 2025.THIRD QUARTER HIGHLIGHTS Third quarter service revenues grew 35.5% year-over-year (YOY) to $11.9M, driven by increased charger u ...

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, e ...

Accessibility StatementSkip Navigation SHELTON, Conn., Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces third quarter 2025 financial results and provides a corporate update. Corpor ...

Key Takeaways AMD's Q3 revenues jumped 36% to $9.25B, with data center, client, and gaming units surpassing expectations.Partnerships with OpenAI and Oracle will expand AMD's AI data center presence using Instinct MI450 GPUs.Despite growth prospects, AMD trades at 65.15x forward earnings, suggesting potential overvaluation risk.Advanced Micro Devices, Inc. (AMD) recently reported a blowout third quarter and raised its outlook, driven by strong demand for its high-performance EPYC and other products. The com ...